When to screen and not to screen

Abstract

Colorectal cancer (CRC) is the third most common cause of cancer-related deaths with treatment of advanced and metastatic CRC (mCRC) remaining palliative at best.¹ The epidermal growth factor receptor (EGFR) has been identified as a therapeutic target for a multitude of malignancies, including mCRC. Ligand-binding to EGFR results in the subsequent activation of multiple signal transduction pathways including the PI3K/AKT and RAS/RAF/MAPK pathways, which are vital for cell growth and survival.² Constitutive activation of these signaling pathways leads to deregulated cellular proliferation, malignant progression, and invasion.³

Keywords: :

• EGFR
• cetuximab
• colon carcinoma
• monoclonal antibodies
• panitumumab
• resistance

This article refers to:

The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies

10.4161/cbt.27741

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.